Sex steroid-producing enzymes in human breast cancer

Endocrine-Related Cancer

Volumn 12, Issue 4, 2005, Pages 701-720

  Suzuki, Takashi ^a   Miki, Yasuhiro ^a   Nakamura, Yasuhiro ^a   Moriya, Takuya ^a   Ito, Kiyoshi ^a   Ohuchi, Noriaki ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; ANDROGEN RECEPTOR; ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ESTERASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; GESTAGEN; GONADORELIN; ISOENZYME; LETROZOLE; MESSENGER RNA; OXIDOREDUCTASE INHIBITOR; PROGESTERONE RECEPTOR; SEX HORMONE; STEROID 5ALPHA REDUCTASE; STERYL SULFATASE; TAMOXIFEN; TESTOSTERONE 17BETA DEHYDROGENASE;

BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER TISSUE; CLINICAL TRIAL; DRUG POTENTIATION; ENZYME LOCALIZATION; ENZYME REGULATION; ESTROGEN SYNTHESIS; HORMONE SYNTHESIS; HUMAN; IMMUNOREACTIVITY; LASER CAPTURE MICRODISSECTION; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVIEW; STROMA CELL;

BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; GONADAL STEROID HORMONES; HUMANS; OXIDOREDUCTASES; SULFOTRANSFERASES;

EID: 29144521213     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00834     Document Type: Review

References (146)

1. Adams JB, Pewnim T, Chandra DP, Archibald L & Foo MS 1979 A correlation between estrogen sulfotransferase levels and estrogen receptor status in human primary breast carcinoma. Cancer Research 39 5124-5126.
2. Adjei AA, Thomae BA, Prondzinski JL, Eckloff BW, Wieben ED & Weinshilboum RM 2003 Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics. British Journal of Pharmacology 139 1373-1382.
3. Aksoy IA, Wood TC & Weinshilboum R 1994 Human liver estrogen sulfotransferase: identification by cDNA cloning and expression. Biochemical and Biophysical Research Communications 200 1621-1629.
4. Angus WG, Larsen MC & Jefcoate CR 1999 Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status. Carcinogenesis 20 947-955.
5. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S & Sasano H 2000 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Research 20 1101-1108.
6. Arun B & Goss P 2004 The role of COX-2 inhibition in breast cancer treatment and prevention. Seminars in Oncology 31 22-29.
7. Baum M 2004 Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 11 217-221.
8. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG & Sahmoud T and the ATAC Trialists' Group 2002 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 2131-2139.
9. Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A & Sahmoud T and the ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group 2003 Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 1802-1810.
10. Bezwoda WR, Mansoor N & Dansey R 1987 Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44 345-349.
11. Bistolas N, Wollenberger U, Jung C & Scheller FW 2005 Cytochrome P450 biosensors - a review. Biosensors and Bioelectronics 20 2408-2423.
12. Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz A, Llopis F, Garcia-Conde J & Romero R 1992 Aromatase activity and estradiol in human breast cancer: its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. Journal of Clinical Oncology 10 438-446.
13. Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Yen J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH & Thijssen JH 2001 Aromatase and COX-2 expression in human breast cancers. Journal of Steroid Biochemistry and Molecular Biology 79 41-47.
14. Brueggemeier RW, Hackett JC & Diaz-Cruz ES 2005 Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews 26 331-345.
15. Bulun SE, Price TM, Aitken J, Mahendroo MS & Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism 77 1622-1628.
16. Chetrite G, Le Nestour E & Pasqualini JR 1998 Human estrogen sulfotransferase (hEST1) activities and its mRNA in various breast cancer cell lines. Effect of the progestin, promegestone (R-5020). Journal of Steroid Biochemistry and Molecular Biology 66 295-302.
17. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F & Pasqualini JR 2000 Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. Journal of Steroid Biochemistry and Molecular Biology 72 23-27.
18. Clyne CD, Speed CJ, Zhou J & Simpson ER 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. Journal of Biological Chemistry 277 20591-20597.
19. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G & Bliss JM and the Intergroup Exemestane Study 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 1081-1092.
20. Diaz-Cruz ES, Shapiro CL & Brueggemeier RW 2005 Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. Journal of Clinical Endocrinology and Metabolism 90 2563-2570.
21. Dufort I, Rheault P, Huang XF, Soucy P & Luu-The V 1999 Characteristics of a highly labile human type 5 17beta-hydroxysteroid dehydrogenase. Endocrinology 140 568-574.
22. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E & Borgs M 2001 Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. Journal of Clinical Oncology 19 3808-3816.
23. El-Rayes BF, Ali S, Heilbrun LK, Lababidi S, Bouwman D, Visscher D & Philip PA 2003 Cytochrome p450 and glutathione transferase expression in human breast cancer. Clinical Cancer Research 9 705-709.
24. Eneman JD, Wood ME & Muss HB 2004 Selecting adjuvant endocrine therapy for breast cancer. Oncology 18 1733-1744, discussion 1744-1745, 1748, 1751-1754.
25. Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE & Chen S 1992 Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. American Journal of Pathology 140 337-343.
26. Evans TR, Rowlands MG, Law M & Coombes RC 1994 Intratumoral oestrone sulphatase activity as a prognostic marker in human breast carcinoma. British Journal of Cancer 69 555-561.
27. Falany JL & Falany CN 1996 Expression of cytosolic sulfotransferases in normal mammary epithelial cells and breast cancer cell lines. Cancer Research 56 1551-1555.
28. Falany CN, Krasnykh V & Falany JL 1995 Bacterial expression and characterization of a cDNA for human liver estrogen sulfotransferase. Journal of Steroid Biochemistry and Molecular Biology 52 529-539.
29. Falany JL, Macrina N & Falany CN 2002 Regulation of MCF-7 breast cancer cell growth by beta-estradiol sulfation. Breast Cancer Research and Treatment 74 167-176.
30. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR & Katzenellenbogen BS 2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562-4574.
31. Galant C, Gala JL, Van Den Berge V, Berliere M, Haumont E & Horsmans Y 2001 Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors. Pharmacology and Toxicology 88 142-146.
32. Geissler WM, Davis DL, Wu L, Bradshaw KD, Patel S, Mendonca BB, Elliston KO, Wilson JD, Russell DW & Andersson S 1994 Male pseudohermaphroditism caused by mutations of testicular 17beta-hydroxysteroid dehydrogenase 3. Nature Genetics 1 34-39.
33. Gingras S, Moriggl R, Groner B & Simard J 1999 Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Molecular Endocrinology 13 66-81.
34. Gingras S, Cote S & Simard J 2000 Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells. Molecular Endocrinology 14 229-240.
35. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ & Pater JL 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine 349 1793-1802.
36. Greeve MA, Allan RK, Harvey JM & Bentel JM 2004 Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). Journal of Molecular Endocrinology 32 793-810.
37. Gunasegaram R, Peh KL, Loganath A & Ratnam SS 1998 Expression of 3beta-hydroxysteroid dehydrogenase-5,4-en isomerase activity by infiltrating ductal human breast carcinoma in vitro. Breast Cancer Research and Treatment 50 117-123.
38. Gunnarsson C, Olsson BM & Stal O and the Southeast Sweden Breast Cancer Group 2001 Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence. Cancer Research 61 8448-8451.
39. Gunnarsson C, Ahnstrom M, Kirschner K, Olsson B, Nordenskjold B, Rutqvist LE, Skoog L & Stal O 2003 Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22 34-40.
40. Hellmold H, Rylander T, Magnusson M, Reihner E, Warner M & Gustafsson JA 1998 Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. Journal of Clinical Endocrinology and Metabolism 83 886-895.
41. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY & Tobias and the ATAC Trialists' Group 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 60-62.
42. Huang Z, Fasco MJ, Figge HL, Keyomarsi K & Kaminsky LS 1996 Expression of cytochromes P450 in human breast tissue and tumors. Drug Metabolism and Disposition: the biological fate of chemicals 24 899-905.
43. Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O & Raunio H 2001 The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue. Breast Cancer Research and Treatment 70 47-54.
44. Isola JJ 1993 Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. Journal of Pathology 170 31-35.
45. Ji Q, Aoyama C, Nien YD, Liu PI, Chen PK, Chang L, Stanczyk FZ & Stolz A 2004 Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Research 64 7610-7617.
46. Jin Y & Penning TM 2001 Steroid 5alpha-reductases and 3alpha-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Practices and Research in Clinical Endocrinology and Metabolism 15 79-94.
47. de Jong PC, Blankenstein MA, van de Ven J, Nortier JW, Blijham GH & Thijssen JH 2001 Importance of local aromatase activity in hormone-dependent breast cancer: a review. Breast 10 91-99.
48. Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR & Iscan M 2003 Expression of CYP3A4 in human breast tumour and non-tumour tissues. Cancer Letters 202 17-23.
49. Kauraniemi P, Barlund M, Monni O & Kallioniemi A 2001 New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Research 61 8235-8240.
50. Kinoshita Y & Chen S 2003 Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha. Cancer Research 63 3546-3555.
51. Kristensen VN & Borresen-Dale AL 2000 Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutation Research 462 323-333.
52. Labrie F, Luu-The V, Labrie C, Belanger A, Simard J, Lin SX & Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews 24 152-182.
53. Lapointe J & Labrie C 2001 Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142 4331-4338.
54. Leers-Sucheta S, Morohashi K, Mason JI & Melner MH 1997 Synergistic activation of the human type II 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester. Journal of Biological Chemistry 272 7960-7967.
55. Lewis MJ, Wiebe JP & Heathcote JG 2004 Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4 27.
56. Liehr JG 2000 Is estradiol a genotoxic mutagenic carcinogen? Endocrine Reviews 21 40-54.
57. Lipton A, Santen RJ, Santner SJ, Harvey HA, Sanders SI & Matthews YL 1992 Prognostic value of breast cancer aromatase. Cancer 70 1951-1955.
58. Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, Wolz G & Brodie A 1996 Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137 3061-3068.
59. Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Cote J, Berube D, Gagne R & Labrie F 1989 Characterization of cDNAs for human estradiol 17beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5′-termini in human placenta. Molecular Endocrinology 3 1301-1309.
60. Luu-The V, Dufort I, Pelletier G & Labrie F 2001 Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Molecular and Cellular Endocrinology 171 77-82.
61. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT & Murray GI 1999 Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. Journal of Histochemistry and Cytochemistry 47 1457-1464.
62. MacIndoe JH & Woods GR 1981 Steroid-metabolizing enzymes in human breast cancer cells. II. 5Alpha-reductase, 3alpha-hydroxysteroid oxidoreductase, and 17beta-hydroxysteroid oxidoreductase. Endocrinology 108 1407-1413.
63. Masuyama H, Hiramatsu Y, Kodama J & Kudo T 2003 Expression and potential roles of pregnane X receptor in endometrial cancer. Journal of Clinical Endocrinology and Metabolism 88 4446-4454.
64. Masuyama H, Suwaki N, Tateishi Y, Nakatsukasa H, Segawa T & Hiramatsu Y 2005 The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Molecular Endocrinology 19 1170-1180.
65. Miettinen M, Mustonen M, Poutanen M, Isomaa V, Wickman M, Soderqvist G, Vihko R & Vihko P 1999 17Beta-hydroxysteroid dehydrogenases in normal human mammary epithelial cells and breast tissue. Breast Cancer Research and Treatment 57 175-182.
66. Milewich L, Shaw CE, Doody KM, Rainey WE, Mason JI & Carr BR 1991 3Beta-hydroxysteroid dehydrogenase activity in glandular and extraglandular human fetal tissues. Journal of Clinical Endocrinology and Metabolism 73 1134-1140.
67. Miller WR 1991 Aromatase activity in breast tissue. Journal of Steroid Biochemistry and Molecular Biology 39 783-790.
68. Miller WR & O'Neill J 1987 The importance of local synthesis of estrogen within the breast. Steroids 50 537-548.
69. Miller WR, Anderson TJ & Jack WJ 1990 Relationship between tumour aromatase activity, tumour characteristics and response to therapy. Journal of Steroid Biochemistry and Molecular Biology 37 1055-1059.
70. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G & Dixon JM 2003 An integrated view of aromatase and its inhibition. Journal of Steroid Biochemistry and Molecular Biology 86 413-421.
71. Miyoshi Y, Ando A, Shiba E, Taguchi T, Tamaki Y & Noguchi S 2001 Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. International Journal of Cancer 94 685-689.
72. Miyoshi Y, Ando A, Hasegawa S, Ishitobi M, Taguchi T, Tamaki Y & Noguchi S 2003 High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer. Clinical Cancer Research 9 2288-2293.
73. Modugno F, Knoll C, Kanbour-Shakir A & Romkes M 2003 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Research and Treatment 82 191-197.
74. Newman SP, Purohit A, Ghilchik MW, Potter BV & Reed MJ 2000 Regulation of steroid sulphatase expression and activity in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 75 259-264.
75. Nussbaumer P & Billich A 2004 Steroid sulfatase inhibitors. Medical Research Reviews 24 529-576.
76. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T 2002 Testosterone and 5alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecology and Endocrinology 16 113-120.
77. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361.
78. Osborne CK, Shou J, Massarweh S & Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clinical Cancer Research 11 865s-870s.
79. Oyama T, Morita M, Isse T, Kagawa N, Nakata S, So T, Mizukami M, Ichiki Y, Ono K, Sugaya M, Uramoto H, Yoshimatsu T, Hanagiri T, Sugio K, Kawamoto T & Yasumoto K 2005 Immunohistochemical evaluation of cytochrome P450 (CYP) and p53 in breast cancer. Frontiers in Bioscience 10 1156-1161.
80. Parker KL & Schimmer BP 1997 Steroidogenic factor 1: a key determinant of endocrine development and function. Endocrine Reviews 18 361-377.
81. Pasqualini JR 2003 Differential effects of progestins on breast tissue enzymes. Maturitas 46 S45-S54.
82. Pasqualini JR 2004 The selective estrogen enzyme modulators in breast cancer: a review. Biochimica et Biophysica Acta 1654 123-143.
83. Pasqualini JR & Chetrite GS 2005 Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. Journal of Steroid Biochemistry and Molecular Biology 93 221-236.
84. Pasqualini JR, Maloche C, Maroni M & Chetrite G 1994 Effect of the progestagen promegestone (R-5020) on mRNA of the oestrone sulphatase in the MCF-7 human mammary cancer cells. Anticancer Research 14 1589-1593.
85. Pasqualini JR, Chetrite G, Blacker C, Feinstein MC, Delalonde L, Talbi M & Maloche C 1996 Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 1460-1464.
86. Pelletier G, Luu-The V, Tetu B & Labrie F 1999 Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. Journal of Histochemistry and Cytochemistry 47 731-738.
87. Peltoketo H, Isomaa V, Maentausta O & Vihko R 1998 Complete amino acid sequence of human placental 17beta-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Letters 239 73-77.
88. Penning TM, Burczynski ME, Jez JM, Lin HK, Ma H, Moore M, Ratnam K & Palackal N 2001 Structure - function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Molecular and Cellular Endocrinology 171 137-149.
89. Poirier D 2003 Inhibitors of 17beta-hydroxysteroid dehydrogenases. Current Medical Chemistry 10 453-477.
90. Poutanen M, Isomaa V, Lehto VP & Vihko R 1992a Immunohistochemical analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. International Journal of Cancer 50 386-390.
91. Poutanen M, Moncharmont B & Vihko R 1992b 17-Hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Research 52 290-294.
92. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM & Reed MJ 1995 Aromatase activity and interleukin-6 production by normal and malignant breast tissues. Journal of Clinical Endocrinology and Metabolism 80 3052-3058.
93. Purohit A, Newman SP & Reed MJ 2002 The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Research 4 65-69.
94. Qian Y, Deng C & Song WC 1998 Expression of estrogen sulfotransferase in MCF-7 cells by cDNA transfection suppresses the estrogen response: potential role of the enzyme in regulating estrogen-dependent growth of breast epithelial cells. Journal of Pharmacology and Experimental Therapeutics 286 555-560.
95. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, Tremblay MR, Poirier D & Lin SX 2002 A concerted, rational design of type 1 17beta- hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. FASEB Journal 16 1829-1831.
96. Raunio H, Hakkola J & Pelkonen O 2005 Regulation of CYP3A genes in the human respiratory tract. Chemico-biological Interactactions 151 53-62.
97. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A & Secreto G 1995 Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology 52 541-546.
98. Reed MJ & Purohit A 2001 Aromatase regulation and breast cancer. Clinical Endocrinology 54 563-571.
99. Reed MJ, Rea D, Duncan LJ & Parker MG 1994 Regulation of estradiol 17beta-hydroxysteroid dehydrogenase expression and activity by retinoic acid in T47D breast cancer cells. Endocrinology 135 4-9.
100. Reed MJ, Purohit A, Woo LW, Newman SP & Potter BV 2005 Steroid sulfatase: molecular biology, regulation, and inhibition. Endocrine Reviews 26 171-202.
101. Rheaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, Trudel C, Luu-The V, Simard J & Labrie F 1991 Structure and expression of a new complementary DNA encoding the almost exclusive 3beta-hydroxysteroid dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads. Molecular Endocrinology 5 1147-1157.
102. Robertson JF & Blamey RW 2003 The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women. European Journal of Cancer 39 861-869.
103. Russell DW & Wilson JD 1994 Steroid 5alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 25-61.
104. Saeki T, Takashima S, Sasaki H, Hanai N & Salomon DS 1999 Localization of estrone sulfatase in human breast carcinomas. Breast Cancer 6 331-337.
105. Sakamoto H, Utsumi T, Honda S, Yoshimura N, Sasaki E & Harada N 2002 The intraclinological estrogen metabolism in breast cancer cell lines. Program of the 6th International Aromatase Conference, Kyoto, Japan, p 113 (Abstract P 6-2).
106. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R & Santner SJ 1994 Stromal spindle cells contain aromatase in human breast tumors. Journal of Clinical Endocrinology and Metabolism 79 627-632.
107. Santner SJ, Feil PD & Santen RJ 1984 In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. Journal of Clinical Endocrinology and Metabolism 59 29-33.
108. Sasano H & Harada N 1998 Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. Endocrine Reviews 19 593-607.
109. Sasano H, Nagura H, Harada N, Goukon Y & Kimura M 1994 Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Human Pathology 5 530-533.
110. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG & Nagura H 1996 Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. Journal of Clinical Endocrinology and Metabolism 81 4042-4046.
111. Sasano H, Edwards DP, Anderson TJ, Silverberg SG, Evans DB, Santen RJ, Ramage P, Simpson ER, Bhatnagar AS & Miller WR 2003 Validation of new aromatase monoclonal antibodies for immunohistochemistry: progress report. Journal of Steroid Biochemistry and Molecular Biology 86 239-244.
112. Sebastian S, Takayama K, Shozu M & Bulun SE 2002 Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Molecular Endocrinology 16 2243-2254.
113. Shenton KC, Dowsett M, Lu Q, Brodie A, Sasano H, Sacks NP & Rowlands MG 1998 Comparison of biochemical aromatase activity with aromatase immunohistochemistry in human breast carcinomas. Breast Cancer Research and Treatment 49 S101-S107; discussion S109-S119.
114. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I & Coombes RC 1989 Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Research 49 2588-2591.
115. Simard J & Gingras S 2001 Crucial role of cytokines in sex steroid formation in normal and tumoral tissues. Molecular and Cellular Endocrinology 171 25-40.
116. Simpson ER & Davis SR 2001 Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142 4589-4594.
117. 2. Endocrine-Related Cancer 6 139-147.
118. Sirianni R, Seely JB, Attia G, Stocco DM, Carr BR, Pezzi V & Rainey WE 2002 Liver receptor homologue-1 is expressed in human steroidogenic tissues and activates transcription of genes encoding steroidogenic enzymes. Journal of Endocrinology 174 R13-R17.
119. Somboonporn W & Davis SR and the National Health and Medical Research Council 2004 Testosterone effects on the breast: implications for testosterone therapy for women. Endocrine Reviews 25 374-388.
120. Sonne-Hansen K & Lykkesfeldt AE 2005 Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Journal of Steroid Biochemistry and Molecular Biology 93 25-34.
121. Speirs V, Green AR, Walton DS, Kerin MJ, Fox JN, Carleton PJ, Desai SB & Atkin SL 1998 Short-term primary culture of epithelial cells derived from human breast tumours. British Journal of Cancer 78 1421-1429.
122. Spink BC, Katz BH, Hussain MM, Pang S, Connor SP, Aldous KM, Gierthy JF & Spink DC 2000 SULT1A1 catalyzes 2-methoxyestradiol sulfonation in MCF-7 breast cancer cells. Carcinogenesis 21 1947-1957.
123. Surmacz E & Bartucci M 2004 Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. Journal of Experimental Clinical Cancer Research 23 385-394.
124. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M & Sasano H 2000a 17Beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. British Journal of Cancer 82 518-523.
125. Suzuki T, Sasano H, Andersson S & Mason JI 2000b 3Beta-hydroxysteroid dehydrogenase/delta5- >4-isomerase activity associated with the human 17beta-hydroxysteroid dehydrogenase type 2 isoform. Journal of Clinical Endocrinology and Metabolism 85 3669-3672.
126. Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T & Sasano H 2001a 5Alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257.
127. Suzuki T, Moriya T, Sugawara A, Ariga N, Takabayashi H & Sasano H 2001b Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Research and Treatment 65 31-40.
128. Suzuki T, Murry BA, Darnel AD & Sasano H 2002 Progesterone metabolism in human leukemic monoblast U937 cells. Endocrine Journal 49 539-546.
129. Suzuki T, Nakata T, Miki Y, Kaneko C, Moriya T, Ishida T, Akinaga S, Hirakawa H, Kimura M & Sasano H 2003 Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research 63 2762-2770.
130. Suzuki T, Miki Y, Moriya T, Shimada N, Ishida T, Hirakawa H, Ohuchi N & Sasano H 2004 Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Research 64 4670-4676.
131. Tremblay Y & Beaudoin C 1993 Regulation of 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase messenger ribonucleic acid levels by cyclic adenosine 3′,5′-monophosphate and phorbol myristate acetate in human choriocarcinoma cells. Molecular Endocrinology 7 355-364.
132. Tseng L, Mazella J, Lee LY & Stone ML 1983 Estrogen sulfatase and estrogen sulfotransferase in human primary mammary carcinoma. Journal of Steroid Biochemistry 4 1413-1417.
133. Tsuchiya Y, Nakajima M, Kyo S, Kanaya T, Inoue M & Yokoi T 2004 Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Research 64 3119-3125.
134. Utsumi T, Harada N, Maruta M & Takagi Y 1996 Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. Journal of Clinical Endocrinology and Metabolism 81 2344-2349.
135. Utsumi T, Yoshimura N, Takeuchi S, Ando J, Maruta M, Maeda K & Harada N 1999 Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Research 59 377-381.
136. Vihko P, Herrala A, Harkonen P, Isomaa V, Kaija H, Kurkela R, Li Y, Patrikainen L, Pulkka A, Soronen P & Torn S 2005 Enzymes as modulators in malignant transformation. Journal of Steroid Biochemistry and Molecular Biology 93 277-283.
137. Wiebe JP, Muzia D, Hu J, Szwajcer D, Hill SA & Seachrist JL 2000 The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Research 60 936-943.
138. Wiebe JP, Lewis MJ, Cialacu V, Pawlak KJ & Zhang G 2005 The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics. Journal of Steroid Biochemistry and Molecular Biology 93 201-208.
139. Wu L, Einstein M, Geissler WM, Chan HK, Ellison KO & Andersson S 1993 Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. Journal of Biological Chemistry 168 12964-12969.
140. Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N & Hayashi S 2005 Tumor-stromal interaction through the estrogen-signaling pathway in human breast cancer. Cancer Research 65 4653-4662.
141. Yamamoto Y, Yamashita J, Toi M, Muta M, Nagai S, Hanai N, Furuya A, Osawa Y, Saji S & Ogawa M 2003 Immunohistochemical analysis of estrone sulfatase and aromatase in human breast cancer tissues. Oncology Reports 10 791-796.
142. Yang C, Zhou D & Chen S 1998 Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Research 58 5695-5700.
143. Yoshimura N, Harada N, Bukholm I, Karesen R, Borresen-Dale AL & Kristensen VN 2004 Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. Breast Cancer Research 6 R46-R55.
144. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 5739-5742.
145. Zhou J, Gurates B, Yang S, Sebastian S & Bulun SE 2001 Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Research 61 2328-2334.
146. 2, liver receptor homologue-1, and aromatase in breast cancer. Cancer Research 65 657-663.